| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 74 | 2026 | 120 | 26.840 |
Why?
|
| Skin | 26 | 2026 | 409 | 6.730 |
Why?
|
| Melanocytes | 20 | 2025 | 76 | 5.700 |
Why?
|
| Hypopigmentation | 11 | 2023 | 15 | 5.270 |
Why?
|
| Autoimmunity | 14 | 2026 | 247 | 3.480 |
Why?
|
| Skin Pigmentation | 9 | 2025 | 33 | 3.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 14 | 2025 | 667 | 3.070 |
Why?
|
| Autoimmune Diseases | 7 | 2025 | 238 | 2.400 |
Why?
|
| Alopecia Areata | 6 | 2018 | 10 | 2.370 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2025 | 20 | 2.290 |
Why?
|
| Immunotherapy | 4 | 2020 | 265 | 1.960 |
Why?
|
| T-Lymphocytes | 7 | 2026 | 1006 | 1.800 |
Why?
|
| Chemokines | 4 | 2021 | 93 | 1.690 |
Why?
|
| Interferon-gamma | 11 | 2024 | 574 | 1.670 |
Why?
|
| Disease Models, Animal | 13 | 2025 | 2283 | 1.610 |
Why?
|
| Chemokine CXCL10 | 11 | 2023 | 56 | 1.570 |
Why?
|
| Dermatology | 4 | 2023 | 66 | 1.540 |
Why?
|
| Pyrazoles | 6 | 2022 | 88 | 1.490 |
Why?
|
| Humans | 97 | 2026 | 64869 | 1.460 |
Why?
|
| Immunologic Memory | 6 | 2021 | 281 | 1.460 |
Why?
|
| Blister | 2 | 2024 | 14 | 1.370 |
Why?
|
| Keratinocytes | 5 | 2026 | 71 | 1.360 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2022 | 219 | 1.360 |
Why?
|
| Melanoma, Experimental | 2 | 2021 | 42 | 1.340 |
Why?
|
| Receptors, CXCR3 | 5 | 2023 | 35 | 1.330 |
Why?
|
| Skin Diseases | 4 | 2022 | 80 | 1.290 |
Why?
|
| Animals | 41 | 2026 | 21382 | 1.250 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 793 | 1.080 |
Why?
|
| Mice | 27 | 2026 | 11098 | 1.040 |
Why?
|
| Chemokine CXCL9 | 6 | 2023 | 23 | 0.990 |
Why?
|
| Simvastatin | 2 | 2017 | 26 | 0.950 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2017 | 173 | 0.920 |
Why?
|
| Ultraviolet Therapy | 6 | 2025 | 12 | 0.900 |
Why?
|
| Dermatitis, Irritant | 1 | 2024 | 3 | 0.870 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2024 | 9 | 0.870 |
Why?
|
| Signal Transduction | 8 | 2020 | 3146 | 0.860 |
Why?
|
| Pyrimidines | 8 | 2022 | 146 | 0.840 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2021 | 16 | 0.820 |
Why?
|
| Interferon Type I | 3 | 2026 | 197 | 0.810 |
Why?
|
| Immunity, Innate | 8 | 2021 | 829 | 0.710 |
Why?
|
| Nitriles | 6 | 2022 | 84 | 0.710 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 2021 | 6 | 0.710 |
Why?
|
| Epidermis | 3 | 2025 | 35 | 0.700 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2021 | 7 | 0.690 |
Why?
|
| Receptors, CCR5 | 1 | 2021 | 59 | 0.680 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 51 | 0.680 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 151 | 0.680 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 37 | 0.670 |
Why?
|
| Biological Products | 1 | 2022 | 92 | 0.660 |
Why?
|
| Cross-Priming | 1 | 2020 | 15 | 0.660 |
Why?
|
| Hair Dyes | 2 | 2017 | 5 | 0.640 |
Why?
|
| Immunity, Cellular | 4 | 2019 | 172 | 0.630 |
Why?
|
| Efficiency | 1 | 2019 | 39 | 0.590 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 198 | 0.590 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 1223 | 0.580 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 3467 | 0.580 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 380 | 0.570 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 39 | 0.560 |
Why?
|
| Interleukin-15 | 1 | 2018 | 25 | 0.560 |
Why?
|
| Male | 25 | 2026 | 30935 | 0.560 |
Why?
|
| Adult | 19 | 2026 | 17277 | 0.560 |
Why?
|
| Melanoma | 1 | 2021 | 332 | 0.540 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 241 | 0.540 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 214 | 0.530 |
Why?
|
| Skin Lightening Preparations | 1 | 2017 | 3 | 0.520 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 71 | 0.510 |
Why?
|
| Mice, Transgenic | 6 | 2025 | 1289 | 0.510 |
Why?
|
| Female | 25 | 2026 | 33895 | 0.490 |
Why?
|
| Stress, Physiological | 2 | 2016 | 209 | 0.490 |
Why?
|
| Bullying | 1 | 2016 | 16 | 0.480 |
Why?
|
| Phenols | 1 | 2017 | 77 | 0.480 |
Why?
|
| Antibodies | 1 | 2017 | 185 | 0.480 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 431 | 0.480 |
Why?
|
| Severity of Illness Index | 9 | 2026 | 1553 | 0.470 |
Why?
|
| Adolescent | 9 | 2026 | 6298 | 0.460 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 433 | 0.460 |
Why?
|
| Young Adult | 8 | 2026 | 4784 | 0.460 |
Why?
|
| Melanins | 1 | 2015 | 27 | 0.460 |
Why?
|
| Organ Specificity | 1 | 2016 | 198 | 0.450 |
Why?
|
| Hair | 1 | 2015 | 81 | 0.450 |
Why?
|
| Quality of Life | 7 | 2025 | 1256 | 0.440 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 86 | 0.440 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2021 | 636 | 0.430 |
Why?
|
| Middle Aged | 13 | 2026 | 18161 | 0.430 |
Why?
|
| Psoriasis | 2 | 2016 | 60 | 0.420 |
Why?
|
| Biomarkers | 4 | 2024 | 1472 | 0.420 |
Why?
|
| Genetic Vectors | 1 | 2020 | 973 | 0.410 |
Why?
|
| Treatment Outcome | 11 | 2023 | 5769 | 0.390 |
Why?
|
| Biopsy | 3 | 2024 | 454 | 0.390 |
Why?
|
| Dermatologic Agents | 2 | 2024 | 21 | 0.380 |
Why?
|
| Phototherapy | 6 | 2025 | 33 | 0.370 |
Why?
|
| Double-Blind Method | 5 | 2022 | 740 | 0.370 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 116 | 0.360 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 5 | 0.360 |
Why?
|
| Dermatitis, Atopic | 2 | 2022 | 27 | 0.350 |
Why?
|
| RNA, Small Interfering | 5 | 2026 | 980 | 0.350 |
Why?
|
| Scleroderma, Localized | 2 | 2023 | 11 | 0.350 |
Why?
|
| Ureteral Obstruction | 1 | 2021 | 29 | 0.350 |
Why?
|
| Janus Kinase 1 | 4 | 2026 | 17 | 0.350 |
Why?
|
| Suction | 2 | 2024 | 33 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 129 | 0.340 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 361 | 0.340 |
Why?
|
| Adenosine | 1 | 2021 | 78 | 0.340 |
Why?
|
| Adaptive Immunity | 3 | 2017 | 105 | 0.330 |
Why?
|
| Consensus | 5 | 2026 | 181 | 0.330 |
Why?
|
| Specimen Handling | 2 | 2024 | 61 | 0.320 |
Why?
|
| Case-Control Studies | 4 | 2026 | 1134 | 0.320 |
Why?
|
| Dermatitis, Contact | 1 | 2010 | 12 | 0.320 |
Why?
|
| gp100 Melanoma Antigen | 3 | 2025 | 6 | 0.320 |
Why?
|
| Apoptosis | 1 | 2015 | 1094 | 0.310 |
Why?
|
| Dermatitis | 2 | 2023 | 27 | 0.310 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 562 | 0.310 |
Why?
|
| Receptors, CCR6 | 2 | 2022 | 9 | 0.300 |
Why?
|
| Clonal Anergy | 2 | 2009 | 22 | 0.300 |
Why?
|
| Thrombosis | 1 | 2021 | 205 | 0.300 |
Why?
|
| Exophiala | 1 | 2008 | 1 | 0.290 |
Why?
|
| Leg Dermatoses | 1 | 2008 | 3 | 0.290 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 190 | 0.290 |
Why?
|
| Dermatomycoses | 1 | 2008 | 18 | 0.290 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 326 | 0.290 |
Why?
|
| Inflammation | 5 | 2026 | 1191 | 0.270 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2026 | 279 | 0.260 |
Why?
|
| Oxidative Stress | 2 | 2021 | 319 | 0.260 |
Why?
|
| Fibroblasts | 2 | 2026 | 415 | 0.250 |
Why?
|
| Phenotype | 3 | 2021 | 1232 | 0.250 |
Why?
|
| Photosensitivity Disorders | 1 | 2026 | 5 | 0.240 |
Why?
|
| Melanosis | 1 | 2026 | 10 | 0.240 |
Why?
|
| Janus Kinases | 2 | 2022 | 16 | 0.240 |
Why?
|
| Epitope Mapping | 1 | 2026 | 51 | 0.240 |
Why?
|
| Transcriptome | 2 | 2024 | 396 | 0.240 |
Why?
|
| Gene Silencing | 2 | 2026 | 430 | 0.230 |
Why?
|
| Cytokines | 3 | 2023 | 952 | 0.230 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2026 | 65 | 0.230 |
Why?
|
| STAT1 Transcription Factor | 2 | 2016 | 35 | 0.230 |
Why?
|
| Myeloid Cells | 1 | 2026 | 98 | 0.230 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 750 | 0.230 |
Why?
|
| Administration, Oral | 2 | 2017 | 371 | 0.220 |
Why?
|
| Interleukin-17 | 2 | 2017 | 99 | 0.220 |
Why?
|
| Population Surveillance | 1 | 2026 | 210 | 0.220 |
Why?
|
| Skin Cream | 2 | 2022 | 3 | 0.210 |
Why?
|
| Interleukin-4 | 1 | 2024 | 147 | 0.210 |
Why?
|
| Hearing Loss | 1 | 2025 | 53 | 0.210 |
Why?
|
| Skin Physiological Phenomena | 2 | 2014 | 16 | 0.210 |
Why?
|
| Bleomycin | 2 | 2023 | 35 | 0.210 |
Why?
|
| Uncertainty | 1 | 2023 | 39 | 0.200 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 180 | 0.200 |
Why?
|
| Fibrosis | 2 | 2023 | 172 | 0.190 |
Why?
|
| RNA, Double-Stranded | 1 | 2023 | 112 | 0.190 |
Why?
|
| Ligands | 2 | 2023 | 415 | 0.190 |
Why?
|
| Child | 5 | 2026 | 4609 | 0.190 |
Why?
|
| Skin Transplantation | 1 | 2023 | 154 | 0.190 |
Why?
|
| Photochemotherapy | 1 | 2023 | 46 | 0.190 |
Why?
|
| Swine | 2 | 2026 | 395 | 0.190 |
Why?
|
| Proteomics | 1 | 2024 | 291 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2025 | 532 | 0.190 |
Why?
|
| Cell Differentiation | 3 | 2016 | 1385 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 62 | 0.180 |
Why?
|
| Tissue Distribution | 1 | 2022 | 293 | 0.180 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 988 | 0.180 |
Why?
|
| Autoantigens | 3 | 2021 | 138 | 0.170 |
Why?
|
| Gene Ontology | 1 | 2021 | 37 | 0.170 |
Why?
|
| CD28 Antigens | 2 | 2015 | 61 | 0.170 |
Why?
|
| Epidemiologic Studies | 1 | 2021 | 34 | 0.170 |
Why?
|
| Ointments | 1 | 2020 | 7 | 0.170 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 302 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 261 | 0.170 |
Why?
|
| Piperidines | 2 | 2020 | 74 | 0.170 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 35 | 0.170 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2020 | 53 | 0.160 |
Why?
|
| Vaccinia virus | 1 | 2020 | 69 | 0.160 |
Why?
|
| Aged | 6 | 2025 | 14867 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 59 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2021 | 108 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 173 | 0.160 |
Why?
|
| Republic of Korea | 1 | 2021 | 205 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2021 | 141 | 0.160 |
Why?
|
| Photography | 1 | 2019 | 42 | 0.150 |
Why?
|
| Cell Movement | 2 | 2019 | 538 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 168 | 0.150 |
Why?
|
| Dermatologists | 1 | 2019 | 11 | 0.150 |
Why?
|
| Transcription Factors | 2 | 2004 | 1551 | 0.150 |
Why?
|
| Cell Death | 2 | 2018 | 289 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 52 | 0.150 |
Why?
|
| Inflammasomes | 1 | 2023 | 347 | 0.150 |
Why?
|
| Stem Cell Factor | 1 | 2018 | 27 | 0.140 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2018 | 2 | 0.140 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 69 | 0.140 |
Why?
|
| Depression | 1 | 2025 | 891 | 0.140 |
Why?
|
| Fas Ligand Protein | 1 | 2018 | 40 | 0.140 |
Why?
|
| Pigmentation | 2 | 2015 | 25 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 580 | 0.140 |
Why?
|
| Early Growth Response Protein 2 | 2 | 2010 | 8 | 0.140 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 239 | 0.140 |
Why?
|
| Foundations | 1 | 2018 | 9 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 725 | 0.140 |
Why?
|
| Disease Management | 1 | 2020 | 233 | 0.140 |
Why?
|
| DNA | 2 | 2023 | 851 | 0.140 |
Why?
|
| Child, Preschool | 2 | 2025 | 2058 | 0.140 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 9 | 0.140 |
Why?
|
| Global Health | 1 | 2019 | 180 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2014 | 1034 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 2483 | 0.130 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2018 | 104 | 0.130 |
Why?
|
| Phenylenediamines | 1 | 2017 | 5 | 0.130 |
Why?
|
| Hydroquinones | 1 | 2017 | 8 | 0.130 |
Why?
|
| Pyrroles | 1 | 2017 | 49 | 0.130 |
Why?
|
| Chemokine CXCL11 | 1 | 2017 | 4 | 0.130 |
Why?
|
| Catechols | 1 | 2017 | 7 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 5571 | 0.130 |
Why?
|
| Self Tolerance | 1 | 2017 | 20 | 0.130 |
Why?
|
| Body Surface Area | 1 | 2017 | 11 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2018 | 344 | 0.130 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 211 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2018 | 666 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2021 | 3303 | 0.130 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 43 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 204 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2023 | 370 | 0.120 |
Why?
|
| Immune Complex Diseases | 1 | 2016 | 2 | 0.120 |
Why?
|
| ROC Curve | 1 | 2017 | 292 | 0.120 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 16 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 52 | 0.120 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 52 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 376 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 240 | 0.120 |
Why?
|
| Regeneration | 1 | 2017 | 122 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 663 | 0.110 |
Why?
|
| Antioxidants | 1 | 2017 | 249 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2015 | 98 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 136 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 362 | 0.110 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 49 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2015 | 151 | 0.110 |
Why?
|
| Immunity | 1 | 2014 | 108 | 0.100 |
Why?
|
| Scalp | 1 | 2013 | 29 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2026 | 6826 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 193 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 37 | 0.100 |
Why?
|
| High Mobility Group Proteins | 1 | 2013 | 27 | 0.100 |
Why?
|
| Neutrophils | 1 | 2016 | 395 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2023 | 373 | 0.090 |
Why?
|
| Ultraviolet Rays | 2 | 2026 | 146 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 2090 | 0.090 |
Why?
|
| Renal Circulation | 1 | 2021 | 14 | 0.090 |
Why?
|
| Intestines | 1 | 2013 | 178 | 0.090 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 145 | 0.090 |
Why?
|
| Incidence | 2 | 2026 | 1412 | 0.090 |
Why?
|
| Methylation | 1 | 2021 | 129 | 0.090 |
Why?
|
| Cells, Cultured | 3 | 2026 | 2188 | 0.080 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2010 | 52 | 0.080 |
Why?
|
| Toxoplasmosis | 1 | 2010 | 21 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2023 | 738 | 0.080 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2008 | 3 | 0.070 |
Why?
|
| Itraconazole | 1 | 2008 | 14 | 0.070 |
Why?
|
| DNA, Fungal | 1 | 2008 | 58 | 0.070 |
Why?
|
| Culture Media | 1 | 2008 | 79 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2009 | 166 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 152 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 405 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2008 | 130 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 208 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 1982 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 414 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 2696 | 0.060 |
Why?
|
| Zinc Fingers | 2 | 2004 | 105 | 0.060 |
Why?
|
| Dermatomyositis | 1 | 2026 | 9 | 0.060 |
Why?
|
| Injections, Intradermal | 1 | 2026 | 12 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2026 | 110 | 0.060 |
Why?
|
| Mice, Hairless | 1 | 2025 | 19 | 0.060 |
Why?
|
| Patient Health Questionnaire | 1 | 2025 | 6 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2756 | 0.060 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2025 | 7 | 0.060 |
Why?
|
| Algorithms | 2 | 2023 | 1040 | 0.060 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2025 | 26 | 0.060 |
Why?
|
| Antigens, Ly | 2 | 2016 | 44 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2018 | 2146 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2025 | 198 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2004 | 64 | 0.050 |
Why?
|
| Clone Cells | 1 | 2004 | 112 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1686 | 0.050 |
Why?
|
| Cell Line | 2 | 2009 | 2033 | 0.050 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2026 | 281 | 0.050 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 80 | 0.050 |
Why?
|
| Recurrence | 1 | 2026 | 655 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 181 | 0.050 |
Why?
|
| Stem Cells | 1 | 2025 | 275 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 55 | 0.050 |
Why?
|
| NLR Proteins | 1 | 2023 | 11 | 0.050 |
Why?
|
| Ownership | 1 | 2022 | 19 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2022 | 50 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2022 | 63 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2022 | 21 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 47 | 0.050 |
Why?
|
| Acne Vulgaris | 1 | 2022 | 23 | 0.050 |
Why?
|
| Pruritus | 1 | 2022 | 31 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 869 | 0.050 |
Why?
|
| Caspase 1 | 1 | 2023 | 112 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2023 | 153 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2023 | 168 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2004 | 959 | 0.050 |
Why?
|
| Emollients | 1 | 2021 | 4 | 0.040 |
Why?
|
| Disease Progression | 1 | 2025 | 1212 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 1579 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 249 | 0.040 |
Why?
|
| North Carolina | 1 | 2020 | 69 | 0.040 |
Why?
|
| Mental Health | 1 | 2023 | 362 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 480 | 0.040 |
Why?
|
| Lighting | 1 | 2019 | 14 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 76 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2026 | 2609 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 87 | 0.040 |
Why?
|
| Health Personnel | 1 | 2023 | 385 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 46 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 426 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 132 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 211 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 797 | 0.040 |
Why?
|
| RNA Interference | 1 | 2022 | 642 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2018 | 109 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2000 | 490 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2000 | 350 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1631 | 0.030 |
Why?
|
| Janus Kinase 3 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2018 | 171 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2018 | 184 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 269 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 87 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1569 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 91 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1112 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2000 | 631 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 460 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 907 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 733 | 0.030 |
Why?
|
| Endotoxins | 1 | 2016 | 81 | 0.030 |
Why?
|
| Mast Cells | 1 | 2016 | 51 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 794 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 64 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 860 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 22 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 112 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 449 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 181 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 107 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2013 | 3 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2013 | 10 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 12 | 0.020 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 9 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 16 | 0.020 |
Why?
|
| Interleukins | 1 | 2013 | 86 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 391 | 0.020 |
Why?
|
| Base Sequence | 2 | 2009 | 1328 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 69 | 0.020 |
Why?
|
| Rheology | 1 | 2013 | 83 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 197 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 283 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 160 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 966 | 0.020 |
Why?
|
| Toxoplasma | 1 | 2010 | 34 | 0.020 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2010 | 88 | 0.020 |
Why?
|
| Macrophages | 1 | 2016 | 1050 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2009 | 28 | 0.020 |
Why?
|
| Columbidae | 1 | 2009 | 15 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2009 | 69 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 300 | 0.020 |
Why?
|
| Antigens | 1 | 2009 | 145 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2009 | 200 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 700 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 5401 | 0.010 |
Why?
|
| Taxes | 1 | 2000 | 6 | 0.010 |
Why?
|
| Snail Family Transcription Factors | 1 | 2000 | 29 | 0.010 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2000 | 14 | 0.010 |
Why?
|
| Government Programs | 1 | 2000 | 19 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2000 | 29 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2000 | 37 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 115 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 234 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2000 | 173 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2000 | 66 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2000 | 160 | 0.010 |
Why?
|
| Health Surveys | 1 | 2000 | 317 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2000 | 165 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 210 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 286 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 367 | 0.010 |
Why?
|
| Binding Sites | 1 | 2000 | 920 | 0.010 |
Why?
|
| Prevalence | 1 | 2000 | 1437 | 0.010 |
Why?
|
| Health Promotion | 1 | 2000 | 512 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 1775 | 0.010 |
Why?
|
| Chromatin | 1 | 2000 | 639 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2000 | 552 | 0.010 |
Why?
|
| Massachusetts | 1 | 2000 | 2142 | 0.010 |
Why?
|